Some remarkable results are the decline of PSA after combination of metformin with bicalutamide after 8 weeks (42.1% bicalutamide + metformin vs 11.1% only bicalutamide) in PC patients with overweight (ClinicalTrial.gov ID NCT02614859), and with castration after 7 months (placebo PSA 58.2 ng/mL vs metformin PSA 8.36 ng/mL, ClinicalTrial.gov ID NCT01620593, [191]), and its detection in the prostatic tissue after consumption for 12 weeks, but without changes in tumor progression markers (ClinicalTrials.gov ID NCT01433913, [192])
GLP-1 receptor agonists like semaglutide and liraglutide intentionally slow gastric emptying as part of their therapeutic mechanism, but distinguishing this expected effect from true gastroparesis presents diagnostic challenges
PASQUALE TOLOMEO DR
Only 0.2% of all patients (n=7,660) developed NAION
[1] For licensed medical professionals only
We track not just your weight but your metabolic health because the goal is a healthier body, not just a smaller number on the scale
